Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Chrisanthar, R; Knappskog, S; Løkkevik, E; Anker, G; Ostenstad, B; Lundgren, S; Risberg, T; Mjaaland, I; Skjønsberg, G; Aas, T; Schlichting, E; Fjösne, HE; Nysted, A; Lillehaug, JR; Lønning, PE 
Titel:
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. 
Abstract:
TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer patients receiving paclitaxel or epirubicin monotherapy.Each patient was randomly assigned to treatmen...    »
 
Zeitschriftentitel:
PLoS ONE 
Jahr:
2011 
Band / Volume:
Heft / Issue:
Seitenangaben Beitrag:
e19249 
Sprache:
eng 
TUM Einrichtung:
Frauenklinik und Poliklinik